Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

BACKGROUND: The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow microenvironment and are refractory to imatinib. Hematopoietic cytokine receptor...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Okabe, Seiichi, Tauchi, Tetsuzo, Katagiri, Seiichiro, Tanaka, Yuko, Ohyashiki, Kazuma
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2014
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012544/
https://ncbi.nlm.nih.gov/pubmed/24775308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-7-37
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires